<SEC-DOCUMENT>0001193125-15-262754.txt : 20150724
<SEC-HEADER>0001193125-15-262754.hdr.sgml : 20150724
<ACCEPTANCE-DATETIME>20150724161529
ACCESSION NUMBER:		0001193125-15-262754
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20150721
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150724
DATE AS OF CHANGE:		20150724

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Paratek Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001178711
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330960223
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36066
		FILM NUMBER:		151004800

	BUSINESS ADDRESS:	
		STREET 1:		75 KNEELAND STREET
		STREET 2:		6TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02111
		BUSINESS PHONE:		(617) 275-0040

	MAIL ADDRESS:	
		STREET 1:		75 KNEELAND STREET
		STREET 2:		6TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Transcept Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20090130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVACEA INC
		DATE OF NAME CHANGE:	20020724
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d152427d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): July&nbsp;21, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Paratek Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36066</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>33-0960223</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File No.)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>75 Park Plaza, 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02116 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address
of principal executive offices and zip code) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (617)&nbsp;275-0040 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Entry into a Material Definitive Agreement. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;23, 2015, Paratek Pharmaceuticals, Inc. (the
&#147;Company&#148;) entered into Amendment No.&nbsp;1 (the &#147;Amendment&#148;) to the Tax Benefit Preservation Plan (the &#147;Tax Benefit Plan&#148;), dated as of September&nbsp;13, 2013, by and between the Company and American Stock Transfer
and Trust Company, LLC, as rights agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Amendment accelerates the expiration of the Company&#146;s preferred share purchase rights (the
&#147;Rights&#148;) from the close of business on September&nbsp;12, 2016, to 4:00 p.m., New York City time, on July&nbsp;23, 2015, and has the effect of terminating the Tax Benefit Plan on that date. At the time of the termination of the Tax
Benefit Plan, all of the Rights distributed to holders of the Company&#146;s common stock pursuant to the Tax Benefit Plan expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is a
summary of the terms of the Amendment. The summary does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which is attached as Exhibit 4.1 and incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Termination of a Material Definitive Agreement. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth under Item&nbsp;1.01 is
incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;3.03</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Material Modifications to Rights of Security Holders. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth under Item&nbsp;1.01 is
incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;21, 2015, upon recommendation of the Nominating and Corporate Governance Committee of the
Board of Directors, the Board of Directors elected Timothy Franson, M.D. as a director, effective immediately. The Board of Directors appointed Dr.&nbsp;Franson to serve as a member of the Board of Directors as a Class I director for a term expiring
at the Company&#146;s 2016 annual meeting of stockholders, or until his earlier resignation or removal or his successor is duly elected and qualified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Franson currently serves as the Chief Medical Officer for YourEncore. Dr.&nbsp;Franson holds a Bachelor of Science in pharmacy from Drake University
and a Doctor of Medicine from the University of Illinois College of Medicine. He is board certified in Internal Medicine and Infectious Diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There
is no arrangement or understanding between Dr.&nbsp;Franson and any other person pursuant to which Dr.&nbsp;Franson was appointed as a director. Dr.&nbsp;Franson will be eligible to participate in the Company&#146;s non-employee director
compensation plans and arrangements available to non-employee directors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.03</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Amendments to Articles of Incorporation or Bylaws; Change in Fiscal year. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the
initial adoption of the Tax Benefit Plan, on September&nbsp;13, 2013, the Company filed a Certificate of Designations of Series A Junior Participating Preferred Stock with the Secretary of State of the State of Delaware fixing the rights, powers,
preferences and qualifications of the Series A Junior Participating Preferred Stock issuable upon exercise of the Rights (the &#147;Preferred Shares&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has filed a Certificate of Elimination (the &#147;Certificate of Elimination&#148;) with the Secretary of State of the State of Delaware
eliminating all provisions of the Certificate of Designations. As a result, the status of the Preferred Shares returned to authorized but undesignated shares of the Company&#146;s preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the terms of the Certificate of Elimination. The summary does not purport to be complete and is qualified in its entirety by
reference to the Certificate of Elimination, a copy of which is attached as Exhibit 3.1 and incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;22, 2015, the Company issued a press release announcing the election of
Dr.&nbsp;Franson. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;24, 2015, the Company issued a press release announcing the Amendment. A copy of the press release
is attached as Exhibit&nbsp;99.2 and incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Elimination of Series A Junior Participating Preferred Stock of Paratek Pharmaceutical, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. 1 to Tax Benefit Preservation Plan by and between Paratek Pharmaceuticals, Inc. and American Stock Transfer &amp; Trust Company, LLC, dated as of July 23, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Paratek Pharmaceuticals, Inc. dated July 22, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Paratek Pharmaceuticals, Inc. dated July 24, 2015</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>PARATEK PHARMACEUTICALS, INC.</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: July&nbsp;24, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ William M. Haskel</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">William M. Haskel</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, General Counsel and Corporate Secretary</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Elimination of Series A Junior Participating Preferred Stock of Paratek Pharmaceutical, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. 1 to Tax Benefit Preservation Plan by and between Paratek Pharmaceuticals, Inc. and American Stock Transfer &amp; Trust Company, LLC, dated as of July 23, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Paratek Pharmaceuticals, Inc. dated July 22, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Paratek Pharmaceuticals, Inc. dated July 24, 2015</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d152427dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF ELIMINATION OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERIES A JUNIOR PARTICIPATING PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF PARATEK PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Pursuant to Section&nbsp;151(g) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>General Corporation Law of the State of Delaware) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>ARATEK</SMALL> P<SMALL>HARMACEUTICALS</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation (the
&#147;<B><I>Company</I></B>&#148;), hereby certifies as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>F<SMALL>IRST</SMALL>: </B>The date on which the Company&#146;s
original Certificate of Incorporation was filed with the Delaware Secretary of State was February&nbsp;27, 2001. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>S<SMALL>ECOND</SMALL>: </B>The Company filed on September&nbsp;13, 2013, with the Delaware Secretary of State pursuant to
Section&nbsp;151(g) of the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;) a Certificate of Designations of Series A Junior Participating Preferred Stock designating the rights, powers, preferences and
privileges of the Company&#146;s Series A Junior Participating Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIRD</SMALL>: </B>The Board of Directors of
the Company (the &#147;<B><I>Board</I></B>&#148;), has adopted the following resolutions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>R<SMALL>ESOLVED</SMALL>,</B>
that the Board hereby determines that none of the authorized shares of the series of Preferred Stock, par value $0.001 per share, of the Company, designated as &#147;Series A Junior Participating Preferred Stock&#148; in the Certificate of
Designations filed by the Company with the Delaware Secretary of State on September&nbsp;13, 2013, are outstanding, and that none of the shares of Series A Junior Participating Preferred Stock will be issued subject to such Certificate of
Designations; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; text-indent:2%; font-size:10pt; font-family:Times New Roman"><B>R<SMALL>ESOLVED</SMALL> F<SMALL>URTHER</SMALL></B><SMALL></SMALL>, that the proper officers of the
Company are hereby authorized and directed to take all such actions as they may deem to be necessary or advisable in order to file a certificate with the Delaware Secretary of State to eliminate all provisions set forth in the Certificate of
Designations of Series A Junior Participating Preferred Stock pursuant to Section&nbsp;151(g) of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>F<SMALL>OURTH</SMALL>:</B>
That all provisions set forth in the Certificate of Designations of Series A Junior Participating Preferred Stock are hereby eliminated.<B> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>,</B> Paratek Pharmaceuticals,
Inc. has caused this Certificate of Elimination to be executed by its duly authorized officer on this 24<SUP STYLE="font-size:85%; vertical-align:top">th </SUP>day of July, 2015. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><FONT STYLE="font-size:10pt"><B>P<SMALL>ARATEK</SMALL> P<SMALL>HARMACEUTICALS</SMALL>, I<SMALL>NC</SMALL>.</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ William M. Haskel</P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d152427dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PARATEK PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 1 TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TAX
BENEFIT PRESERVATION PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This AMENDMENT NO. 1 TO THE TAX BENEFIT PRESERVATION PLAN (this &#147;<B><I>Amendment</I></B>&#148;) is
dated as of July&nbsp;23, 2015 (the &#147;<B><I>Effective Date</I></B>&#148;) and amends the Tax Benefit Preservation Plan, dated as of September&nbsp;13, 2013 (the &#147;<B><I>Tax Benefit Plan</I></B>&#148;), by and between Paratek Pharmaceuticals,
Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and American Stock Transfer&nbsp;&amp; Trust Company, LLC, a New York limited liability company, as rights agent (the &#147;<B><I>Rights Agent</I></B>&#148;). Capitalized terms
used in this Amendment and not otherwise defined have the meaning given to them in the Tax Benefit Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in accordance with Section&nbsp;26 of the Tax Benefit Plan, for so long as the Rights are then redeemable, the Company may in its
sole and absolute discretion, and the Rights Agent shall, if the Company so directs, supplement or amend any provision of the Tax Benefit Plan in any respect without the approval of any holders of Rights or Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company has determined to amend the Final Expiration Date so that the Rights terminate and expire on the date hereof; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Rights are currently redeemable, and the Company has requested and directed that the Rights Agent shall join in this Amendment.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, in consideration of the premises and the mutual agreements herein set forth herein, the parties hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<I>Amendment of the Tax Benefit Plan</I>. Section&nbsp;7.1 of the Tax Benefit Plan is hereby amended and restated in its entirety as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <U>Exercise of Rights</U>. Subject to <U>Section 11.1.2</U>&nbsp;and except as otherwise provided herein, the registered
holder of any Right Certificate may exercise the Rights evidenced thereby in whole or in part at any time after the Distribution Date upon surrender of the Right Certificate, with the form of election to purchase and certification on the reverse
side thereof properly completed and duly executed, to the Rights Agent at the office of the Rights Agent designated for such purpose, together with payment of the aggregate Purchase Price for the total number of one one-hundredths of a share of
Series A Preferred (or other securities, cash or other assets) as to which the Rights are exercised, at or prior to the time (the &#147;<I>Expiration Date</I>&#148;) that is the earliest of (i)&nbsp;4:00 p.m., New York City time, on July&nbsp;23,
2015 (the &#147;<I>Final Expiration Date</I>&#148;), (ii)&nbsp;the time at which the Rights are redeemed as provided in&nbsp;<U>Section 23</U>, (iii)&nbsp;the closing of any merger or other acquisition transaction involving the Company pursuant to
an agreement of the type described in&nbsp;<U>Section 13.3</U>&nbsp;at which time the Rights are deemed terminated, (iv)&nbsp;the time at which the Rights are exchanged as provided in&nbsp;<U>Section 27</U>, (v) the close of business on
September&nbsp;12, 2014, if Stockholder Approval has not been obtained by that date, (vi)&nbsp;the close of business on the effective date of the repeal of Section&nbsp;382 if the Board determines that this Tax Benefit Plan is no longer necessary or
desirable for the preservation of the Tax Benefits, or (vii)&nbsp;the time at which the Board determines that the Tax Benefits are fully utilized or no longer available under Section&nbsp;382 or that an ownership change under Section&nbsp;382 would
not adversely impact in any material respect the time period in which the Company could use the Tax Benefits, or materially impair the amount of the Tax Benefits that could be used by the Company in any particular time period, for applicable tax
purposes. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <I>Amendment of Exhibits</I>. The exhibits to the Tax Benefit Plan shall be deemed to be
restated to reflect this Amendment, including all conforming changes.<I>&nbsp;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <I>Other Amendment; Effect of Amendment</I>. Except
as and to the extent expressly modified by this Amendment, the Tax Benefit Plan and the exhibits thereto remain in full force and effect in all respects without any modification. This Amendment will be deemed an amendment to the Tax Benefit Plan and
will become effective on the Effective Date. In the event of a conflict or inconsistency between this Amendment and the Tax Benefit Plan and the exhibits thereto, the provisions of this Amendment will govern.<I>&nbsp;</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <I>Counterparts</I>. This Amendment may be executed in any number of counterparts and each of such counterparts will for all purposes be
deemed to be an original, and all such counterparts will together constitute one and the same instrument, it being understood that all parties need not sign the same counterpart. A signature to this Amendment transmitted electronically (including by
fax and .pdf) will have the same authority, effect and enforceability as an original signature. No party hereto may raise the use of such electronic transmission to deliver a signature, or the fact that any signature or agreement or instrument was
transmitted or communicated through such electronic transmission, as a defense to the formation of a contract, and each party forever waives any such defense, except to the extent such defense relates to lack of authenticity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <I>Severability</I>. If any term, provision, covenant or restriction of this Amendment is held by a court of competent jurisdiction or
other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Amendment will remain in full force and effect and will in no way be affected, impaired or invalidated.<I>&nbsp;</I>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <I>Descriptive Headings</I>. The descriptive headings of the several Sections of this Amendment are inserted for convenience only and
will not control or affect the meaning or construction of any of the provisions hereof.<I>&nbsp;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <I>Further Assurances</I>. Each
of the parties to this Amendment will cooperate and take such action as may be reasonably requested by the other party in order to carry out the provisions and purposes of this Amendment, the Tax Benefit Plan and the transactions contemplated
hereunder and thereunder.<I>&nbsp;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <I>Governing Law</I>. This Amendment will be deemed to be a contract made under the laws of the
State of Delaware and for all purposes will be governed by and construed in accordance with the laws of such State applicable to contracts made and to be performed entirely within such State.<I>&nbsp;</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature page follows</I>]<I> </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the
day and year first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PARATEK PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ William M. Haskel</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">William M. Haskel</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SR. VP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMERICAN STOCK TRANSFER &amp; TRUST COMPANY, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Nespoli</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael Nespoli</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Director</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d152427dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g152427g85v70.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Timothy Franson M.D. Joins Paratek&#146;s Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BOSTON,&nbsp;July 22, 2015&nbsp;(GLOBE NEWSWIRE) &#151;&nbsp;Paratek Pharmaceuticals, Inc.&nbsp;(Nasdaq:PRTK), a biopharmaceutical company focused on the
development and commercialization of innovative therapies based upon tetracycline chemistry, announced today the appointment of&nbsp;Timothy Franson, M.D. as a new, independent director to its board of directors. This appointment, effective as
of&nbsp;July 21, brings Paratek&#146;s total number of directors to seven, five of whom are independent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Tim&#146;s leadership and expertise in the
area of infectious disease, particularly with regards to regulatory compliance, is widely recognized, as are his contributions to policy and research,&#148; said&nbsp;Michael Bigham, Chairman and Chief Executive Officer of Paratek. &#147;We&#146;re
honored to have him join our board and look forward to his contributions as we progress omadacycline toward anticipated commercialization.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I
have been impressed by the progress the Paratek team has made in the past few years, as they&#146;ve moved omadacycline back into clinical development,&#148; said Dr.&nbsp;Franson. &#147;I believe this product has the potential to meet important
needs in the treatment of hospital and community acquired infections, and I&#146;m looking forward to working with Michael and the other board members.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Board-certified in internal medicine and infectious disease, Dr.&nbsp;Franson has authored more than 50 articles in the fields of infectious disease,
epidemiology, pharmacoeconomics and antibiotic utilization. He currently serves as Chief Medical Officer for YourEncore, a consulting group that provides regulatory pre-approval and post-marketing regulatory advice as well as bundled strategic
consulting with regulatory reimbursement and clinical, quality and pharmacovigilance services. Dr.&nbsp;Franson has extensive clinical and regulatory experience in all pre- and post-approval phases of pharmaceutical development (small and large
molecule) relating to interactions with the&nbsp;Food and Drug Administration&nbsp;for policy and product issues, as well as interactions with global regulators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Franson has served on industry working groups with the&nbsp;FDA, including the&nbsp;FDA/IDSA Antimicrobial Guidelines Working Group&nbsp;from 1990
&#150; 1993, where he served as Module Chair. Recently, he served on the NIH-NCATS Treatment of Rare Diseases (TRND) review panel. Dr.&nbsp;Franson recently completed a five-year term as President of&nbsp;US Pharmacopeial Convention&nbsp;(USP),
which establishes drug quality standards enforced by regulators such as the&nbsp;FDA. He remains integrally involved in global public health initiatives through USP as Past President and a member of its Board of Trustees. He also recently joined the
Board of Directors for the&nbsp;Critical Path Institute, which collaborates with the&nbsp;FDA&nbsp;and industry in innovation advances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Paratek
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paratek Pharmaceuticals, Inc.&nbsp;is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon
its expertise in novel tetracycline chemistry. Paratek&#146;s lead product candidate, omadacycline, is an aminomethylcycline, derived from tetracyclines. Paratek has initiated a Phase 3 registration trial in ABSSSI to determine the efficacy and
safety of omadacycline compared to linezolid. A second Phase 3 registration trial in CABP with omadacycline is planned to be initiated before the end of 2015. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Omadacycline is a new once-daily oral and intravenous, broad-spectrum antibiotic being developed for use as
empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community acquired bacterial pneumonia (CABP), urinary tract infections (UTI), and
other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paratek&#146;s second
product candidate, sarecycline, also known as WC 3035, is a new once-daily oral tetracycline-derived compound, designed to provide both a narrow-spectrum of antibiotic activity and favorable tolerability profile, for the treatment of acne and
rosacea in the community setting. Paratek has licensed rights to sarecycline for the treatment of acne in&nbsp;the United States&nbsp;to a subsidiary of&nbsp;Allergan, formerly&nbsp;Warner Chilcott, while retaining rights in the rest of the
world.&nbsp;Allergan&nbsp;is responsible for the clinical development of sarecycline for the treatment of acne in&nbsp;the United States. A Phase 3 program was initiated by&nbsp;Allergan&nbsp;in&nbsp;December 2014&nbsp;for sarecycline for the
treatment of moderate to severe inflammatory acne. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, visit&nbsp;<U>www.paratekpharm.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements, including statements related to progressing omadacycline toward commercialization and having the potential to meet important needs in the treatment of hospital and community acquired infections. All statements, other than
statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as &#147;advancing,&#148; &#147;believe,&#148; &#147;expect,&#148; &#147;well positioned,&#148; &#147;look forward,&#148;
&#147;anticipated,&#148; &#147;continued,&#148; and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the
plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ
materially from those included in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to (i)&nbsp;our need for substantial additional funding to complete the development and
commercialization of our product candidates, (ii)&nbsp;our ability to raise the capital to do so, (iii)&nbsp;our ability to develop our drug candidates for potential commercialization, (iv)&nbsp;the timing and success of our clinical trials,
(v)&nbsp;the potential use and effectiveness of omadacycline and sarecycline, (vi)&nbsp;data to date and trends not being predictive of future results, and (vii)&nbsp;our clinical trials and product candidates not receiving regulatory approval.
These and other risk factors are discussed under &#147;Risk Factors&#148; and elsewhere in our Quarterly Report on Form 10-Q for the quarter ended&nbsp;March 31, 2015, and our other filings with the&nbsp;Securities and Exchange Commission. We
expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>d152427dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g152427g85v70.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Paratek Announces Termination of Tax Benefit Preservation Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BOSTON &#150; July&nbsp;24, 2015</B>&#150; Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a biopharmaceutical company focused on the development and
commercialization of innovative therapies based upon tetracycline chemistry, today announced that its tax benefit preservation plan has been amended to accelerate the expiration date to July&nbsp;22, 2015, effectively terminating the plan as of that
date. Stockholders are not required to take any action as a result of this expiration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the expiration of the plan, Paratek will be
taking routine actions to deregister the related preferred share purchase rights under the Securities Exchange Act of 1934, and to delist the preferred share purchase rights from NASDAQ. These actions are administrative in nature and will have no
effect on the Paratek&#146;s common stock, which continues to be listed on NASDAQ. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Paratek </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise
in novel tetracycline chemistry. Paratek&#146;s lead product candidate, omadacycline, is an aminomethylcycline, derived from tetracyclines. Paratek has initiated a Phase 3 registration trial in ABSSSI to determine the efficacy and safety of
omadacycline compared to linezolid. A second Phase 3 registration trial in CABP with omadacycline is planned to be initiated before the end of 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Omadacycline is a new once-daily oral and intravenous, broad-spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from
serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community acquired bacterial pneumonia (CABP), urinary tract infections (UTI), and other community-acquired bacterial infections,
particularly when antibiotic resistance is of concern to prescribing physicians. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paratek&#146;s second product candidate, sarecycline, also known as WC
3035, is a new once-daily oral tetracycline-derived compound, designed to provide both a narrow-spectrum of antibiotic activity and favorable tolerability profile, for the treatment of acne and rosacea in the community setting. Paratek has licensed
rights to sarecycline for the treatment of acne in the United States to a subsidiary of Allergan, formerly Warner Chilcott, while retaining rights in the rest of the world. Allergan is responsible for the clinical development of sarecycline for the
treatment of acne in the United States. A Phase 3 program was initiated by Allergan in December 2014 for sarecycline for the treatment of moderate to severe inflammatory acne. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, visit www.paratekpharm.com. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g152427g85v70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g152427g85v70.jpg
M_]C_X``02D9)1@`!`0$`E@"7``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``(!`0(!`0("
M`@("`@("`P4#`P,#`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,
M!PD.#PT,#@L,#`S_VP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``]`/X#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]^)\!0<9QTKE_B;\7?#OPD\.G4/$>I6VG6Q!"*['S+AL?=C0?,Y]@
M#7`_MQ?M`:M^SY\*+34M%AM7OM1OUL5EN`2ML#'(Y<*/O'Y,`'U_"O#_`(3_
M`+$GB#X\7-OXR^*>O74T=ZOGI9++YD\L1&5!<?+$A&/E3G'=3T_.>(N,\93Q
M\LDR/#.MB4E*3D^6G3B]I2;W]%OZGU^4<-X>>$6:9K65*@VTDES3FUNHKIZO
M03QO^V?X\_:0\0-X<^%NAW]A:NH$M]L!N=I!^9F)\N!>!URQYVD8Q7Q9XD_;
M6_:W_P""-?QEU*'XGZ+J'Q)^$&K:G)+9W=S=O>PV\<DI8);Z@07BD`X\FX!4
MD?*JK\U?H/\`$7]L'X>?LNZ(/#7@;3+'4[^W!C^S6`"6L$@'!EE7.]^.0NYC
MZC-?*OP)_P"#@CP9XR^(?B3X5_M(^$+/PJZ7MQIK:DU@\^C7D0E*QQW=K*'D
MARN"6/F(0"S>6*]CPCG.IF&-6*Q"S*LHQ]K&*M"FKNRIVTO?=J[=M4CS/$&$
M883"NE0^I4FW[-O64W97<[ZV[;)=+GV+^PU_P4[^$?[?6@"X\$>(5CUR-"]Y
MX>U$"WU6R(/S9B)/F*,C]Y$73D<CI7T+%.'D7GJ.,U^4/[7O_!OOX5^)<5K\
M4/V5O%T'@S770ZCIUG;:DQTF\)&4>QO(B7M2?X=K/'@@*(QDUTG_``1*_P""
ME/QH^,G[2?BW]G_XTVMAJ/B/P#I]W++K!:-;])K2Y@M9;><Q$Q3G=(2)4VYV
M<[]V1^JXS(\-6H3QN63O&&LH2TG#I_V\O-:GPF%S2M3J1PV.C9RTC*/PR_R/
MU!HHKQ?]I3_@H-\'OV/_`!+IVD?$KQWI/A'4-6MWO+."\CF9KB%7"%UV(W`8
MX^M?.4:-2K/V=*+D^R3;_`]NK5A3CSU&DN[T/:**^4&_X+@?LK+U^-/A<<]X
M;H?^TJ]B_9^_;&^%_P"U192S_#SQ]X5\7K;KNGBTV_26>W'K)%D2(/\`>45O
M5R_%4H\]6E**\XM?FC&ECL/5=J=2+?DT_P`F>FT4SS"1P<UY5^TQ^VO\,OV-
M]*TJ\^)OC/2_"5OK4LD-DUVDC&Y:-5+[1&K'"AU)/0;A7/3ISJ24*<7)OHE=
MF]2I&$>:;LEW/6**H^&O$%IXK\/6.J6%Q%=V.I0)=6T\9RDT3J&1P>X*D'\:
MMS.47(J'H5=6N/HKY;UW_@M)^S!X7UR\TS4/C'X7M[_39Y+6ZB,5R3%(C%74
MXB(R&!'7M4-M_P`%N/V5;VYCBC^-?A-6D8*#(MPB@GU9H@%'N37HQR?,)*\:
M$VO\,O\`(XWF6$3LZL?_``)?YGU517+_``M^,/ACXW>$K?7_``?XCT3Q3HES
MQ%?:5>1W=NY[C>A(STR.HKIT)/6O/DFFXR5FCKC-27-%W0M%8?Q'^(FC?";P
M'K'B;Q#J-MI&@Z#:2W^H7LY(BM((U+O(V`3@*">!7)?LX?M7>`?VMO!EUXA^
M'7BG3_%>CV-XVGW%S9AU6*X5$=HR'56!VNIZ8P:I4YN#J*+Y5HW9V7S)E5@I
M*#>KZ=3TFBO-/VD?VN_AW^R!X4L==^)7BK3_``GH^IW@T^TN;M)&6>X,;R>6
M-BL<[(W;D8X/M7CA_P""X/[*O;XT>%\>ODW7_P`:KIH9?BJT>>C2E)=U%M?@
MC"KCL-2ER5*D4^S:7YGU=17RB/\`@N'^RF%R?C5X7_[\W7_QJO3OV:?V\?A/
M^V-=ZQ!\,?&^D^,)=`6*34%LTE4VJREQ&6WJOWC&_3^Z:=;+,92@ZE6C.,5U
M<9)??8=/&X>I)1A--OHFO\SV"BOFSXE_\%=_V<O@W\0M8\*>*/BOX>T;Q#H-
MRUI?V4T5P9+25?O(VV,C(SV-8@_X+@_LI'_FM7AC\(;K_P"-54<JQTES1H3:
M?]U_Y$2S+"1?+*K%-?WE_F?5U%>$?`#_`(*6?`_]JSQ^WA;X<_$;1/%7B!+2
M2_:QMHYED$$;(KR9>,#`+J.N?F%;/QX_;G^%G[+_`(S\/>'?'WC33/#6M^*V
M"Z1:7,4K-?\`[Q8_DV(P^^ZKSCDUC+!8B-3V,J<E+>UG>W>QK'%490]I&:<>
M]U8]>HJ%)F+')&.W'2O+?VE?VV?A=^QY8:;=?$SQSH7A"+5Y'CLUOI&\RYV#
M+LJ*"Q5<C+8VC(!.36%*G.K+DIQ;;Z)7?W(UG4A"+E-V2/6**\HF_;0^'5GX
M.T+Q%<^)HK/0/$MD=2T[4;FRN8;:XM_-BB$AD>-50%YX5`?!;S%QD&O4=/OX
M=5L(+JWD66"YC66-QT=6&01]0:J=*<%>46O5=M_NZA&K"3M%IGS)_P`%6CCX
M&Z!\VTG74P<X_P"7>>O'?#^J?&/]LWP_I^@Z/$?#_@ZUM8[&2<.T5I,J*$)D
MDV[IR<#*(-HS@],GV#_@K`-WP(T,=CKBY[?\N\]>Z?!R"&W^%7AL*J1[M-MC
M@8`YC4_J2:_G['\-2SKC?&X>IB)TJ2I4G-0?*YIW2BW_`"]UU/UK"Y['+.%\
M+6C1C4J.I4Y7-74-KM+J_78\]_9]_80\(_`R*&[E@BU_7H^1J%Y$#Y)](H_N
MQCW&6_VJR_VW/^"8OPD_;]\./;^/?#ENVM10&&S\06`6VU6Q&<@+,!\Z9Y\N
M0,F>=N>:^A-X]1^=&X$$@@X]Z_;N'\KPN14XT\H@J*C_`"Z/U;W;[MGYCFV-
MKYI.53,)NHY?S:_)=EY(_#WQ3^R#^UM_P0T\1W7B;X2ZU/\`$SX4&=KF_P!/
MCMI+F$Q[<L]WIX)>)N#F>V;'\3%%^6JG_!OG\8)OVB?^"PGQ7^($]A'I<WC3
MP]J^MRV<<YG2U>XU2TE:-9"!N52V`<#.,X&:_<:=(W`!(_.OQR_X)'VL5A_P
M<)_M+001QPP0GQ*BQQJ%1`-:ML``<#C-?J.!SN6.P&,]M3BJBIZS6CDN9;VT
MNNY\'B<N6#Q>'5.;Y.?2+UL[/8_94]#7XQ?\'$_AC3_'7_!2?]F?0M6MQ=Z5
MK@M-.O8"S+YT$VL11R)E2&&58C(((]:_9WK7XN_\'&GC"R^'7_!1O]F[Q%J;
M2IIGAZ.VU.\:)#(ZP0:M'+(54?>;:AP.YKR."G/^U$H7OR3M;>_+H>GQ.XK`
MOGVYH[^J/MF/_@@E^R<`<?".W0#@8\1:O_\`)5?F[_P5X_8.TW_@CC\:OAO\
M9?@3JFK>&XM0U*6./3Y;M[I;&ZA02"))'/F/;S1F1'CD9^%^]A@%^YS_`,'*
MW[+X'_(5\:'(R1_PCTH_]FXKX/\`^"C/[:&J_P#!>/X_^`/A+\$O"FM/H>B7
M,MPUY?PA)3)*%C>\F5&98+>",/RS98L1]XHI]O(*.=1Q:>8\ZH6?/SM\O+;^
M\]^QY.;O+98=QP:A[2ZY>6U[W\C]S/A%X_@^*?PF\,>*+9/+M/$FD6NJQ+G[
MJ3PI*H_)A7XL?\%'?!_B/_@LA_P55\<_#OP5<NVB_`_PEJ$$!8[HKG4($)DC
M"G@&:^>"V)SRD!;^'%?J7^UC\;=*_P""<W_!/[6]>AF2./P#X;ATK1(YL-]I
MNEC6ULX\=\R&+/MN/8U\I?\`!M+^S5>>"?V5O$7Q;\0I//XG^+FJR7"7ET2]
MQ-8V\LBJ[$\YEN&NI/\`:4QGIMKQLDJQP-&OF\5L^2G_`(F[W^4;_>>GF5+Z
MW4IY?+K[T_1:?F=I_P`&[?[77_#1'["%EX4U6\FG\4_"FX&A7<<P(F^QD,]D
M[>PCW1?6W.??[Z=@Q48/-?CG\)KA?^"6'_!PAKGA$L=+^'?QZVM:B8%8$DO7
M>6WV'H"E^L]NJ]`DYSVQ^Q2X^49SSZUYW$N'4,4L33^"LE-?]O:M?)W1UY+5
M<L/["?Q4WROY;/YH_"/_`((Z_L/_``O_`&W?VT_VB[#XH>%(O%%GX=U)KBP1
MM0N[0V\DM_>*[`P2Q[MP5!@YZ&OT0UW_`(-__P!DW6]*GME^%S6;RH56XM_$
M>K"6`]F3-RPR.O((XY!K\H?V"?\`@IQ:?\$S_P!KWX\:M=^#=1\9+XMU:6T6
M*TO%MC;&&_NV+$LC9W>8``/[IKZSUS_@ZWTZVTV1K7X':T+@@B/[3X@CCB+8
M)&2(">W3'8\CK7VV?8+/ZN8RE@)S5-J-DIV7PKIS(^9RC%Y3##)8J,>:[O>-
M^KZV/)_V(/#FK?\`!*3_`(+TR?!'0]<O]4\$>+)UTR6*XE#-<6]Q9-=V<CJH
M"^?%)M0N`,@R'`W8K]SX&(0YZ\9QZXK\8_\`@DU^S/\`%G]OC_@HT_[77Q3T
M*?P]X>5GU/1P\;0Q:G,UJ;2UCM5;YVM88"&\X@!V5,;\N1^S1("$D[1DGDU\
MMQA5B\323:=2-.*J-=9ZWN^K/<X=BXT:CM:#G)QO_+T^1^:7_!RA^T??:1^S
MWX2^!_A<W%QXM^,.KQ0O:P\-+90R+B,D?\];IK=`/X@L@]:\;_X)(6VM?\$M
M/^"J_C3]FSQAJK7.D>/]-@N='NL$6]Y>QP&XBD3LN^(W4)/5GMT7DXJQ^S//
M_P`/5O\`@OUXE^(<A;5OAU\#X]NBR9+6KM;,\%HZ=CYMTUU=*>XB7J,`=G_P
M<F?!K5?AC/\`"3]I/P:K6OB3X<ZS%I]Y=!6=(T,OVBSDE7IL6X1XCV;[6`<_
M**]["QIT:=/A^IHZL6Y/M.5G#[DDOF>5B'.I.>;P^Q)*/^%:2^]GZ$?M1_L9
M?#?]M'P?IV@?$SPVOB;2-)OO[2M+<WUS:>5<>6\>_=!)&Q^21Q@G'S=,@$?#
M?_!2_P#X(X?LX?`']@GXI>,O"7PU@T?Q)X>T-[O3[P:UJ4QMY0Z@-LDN&1L!
MC]Y3UK[]_9N^..E?M*_`CPGX]T29)=+\7:5!J<(5@WE;T!:,X_B1MR,.H92#
M7CW_``6/(_X==_&W';PY*/\`Q]*^5R7&XVAC:6&5248\\4XJ32^))Z7/>S+"
MX:OAJE=PBWR-W:5]M#X/_P""%_\`P2R^!7[8/[#:^+_B+X#B\0^(CX@OK'[6
MVL:A;DPQ^7Y:E89T3C<>=N3GK7Z0?LL?\$\_A'^Q'>:[<_"[PE'X6E\1I#'J
M)74KR[^TK$7,?^OEDV[3(_W<?>KYC_X-F/\`E&C'_P!C5J7_`+1K]")#A#]*
MZ^*LQQ<LPQ&'E5DX<S7+S.UD]-+V,L@P6'C@Z-:--*7*M;*^Q^&OP"_91^'_
M`.V/_P`'`7Q_\)?$GP^GB30(6U748[1KN>V`GCN+1%??!(C\+(XQNQS7Z#+_
M`,$$_P!DL(-WPCBSCG_BH]7_`/DJOR_N?'/QQ^'G_!<CX]ZA^S[X=T[Q1X\:
M^U*"6SO8HY(UL3-;&63$DT*Y#B$9WY^8X4]OI<?M2_\`!43[P^#?A$YZ?Z#:
M_P#R?7TN=4<QE.D\-BE3C[.&CJ<O1=+H\#+JN#A&I&O0<WS2UY.;KW/N;]G#
M_@EK\"/V0?B2?%WPX\!Q^&O$+64NGM=C5;Z[+02,C.FV>:11DQIR!GBOSN_X
M.0UQ^WI^S"!V=>G_`&%;.OOK_@F)\1?VB?B5\+O$MS^T;X3TWPGXEMM8\G2H
M+*&*-;BR\B(^81'/,,^:9!R0>.G>OSK_`.#I'Q-+X(_:J^`VMP1133Z+IES?
MQ1R$A)'AOK:15;!!P2H!P0<5Y7#7UB7$$:=>I[224E?FYK^Z[>]V/1SOV,<I
M<J4.2-XNUK?:70_1;_@I=_P4U\$_\$XOA&VJZXXU7Q7J4<B:#X?AD"S:C(HY
MD<_\LX$R"\A'`X4,V!7Q'_P3R_X)L^.O^"AOQNC_`&F/VHS+J$&H,MYX7\*W
M*-'!)"&+0N\)SY5HG!BA))EW&20D'#_&'Q=L/C1\"?VF?AA^T]^TW\/[CQIH
MGC/4QJ!TW55`"0Q@M':FW&%MF1&6:""3(8Q?.I(EK^A7X'?&?PQ^T%\,-"\:
M>$=2M]6\.^(;5;NRNHS@.I!RI7JKJ<JRD`JRL",BIQU"63X*/U-\TJMU*HGH
MNCA%K;S?7H&$J+,L5)XC2,+-4VK-[/FD7O$WPMT'QS:I!K&AZ/JMO'&8!%>6
MD<R+&61RH5E(QOCC./\`84]JZ*VMTM+>.*)%CBB4(BJ,!0!@`#TI4(.<$'FG
M5\5S2:LV?51A%:I'RW_P5=Q_PHWP_N^[_;R;OI]FGS7F?PH_;!\??LP0:/I'
MQ!T>YU#P[<11M8W+!5G$)4%?*D&$EP"!Y9^88QFO7/\`@I[X/U+Q=\"=._LZ
MPN[[^S]56YN#!&S_`&>(03*78`$A06&2!QGTJO\``#]J#X=_'SX>Z=X)U^&U
MM=0%I'9?8-3"-#>E4`#1.?E8G`('#`]!7\ZY[0JOCC$2P^-^J5Y4Z?LW)7A4
MMO!IZ2^3NNA^Q956A_JO15;"_6*2G4YTG[\+[25M5\]'LSVGX3_'3PU\;-$6
M_P##NHV]\B\319VS6Y]'0_,I^HY[9J?XK_&KPK\"?`MWXE\9Z]I7AG0;$9GO
M=0N5@B0]E!)^9CT"C+$\`$U\B?%G]@WQ9\'O$S^)?AA>WDL$;92U@D:._M%)
MR0C9_?(/[IYYQM;''PDG_!,W]J/_`(*]_M":OXD^+OB#6/!O@+3]3GBTR?6K
M4QM'`LAC"Z?IORA<HO\`K7"!MP;,OW:_9O#G'8[-<17P7$E/ZK+#J+<U[T:J
M;:O3\]-5=VOJ?F?&.%PN`HTL5DM3V\:K:4=I0:2?OKMKOUL>G_M8?\'!?C+]
MHOQJ_P`-/V2_!FKZWK&H;H(O$,VG-<7<C!L%[6T(Q&@X)FN<!023&N`Q\T_X
M-[]$\4^&/^"P?Q6TWQW//<^-[/P_K,.OS33K<R2WZZI9_:&>525=BY8EE)!.
M2"1S7W#XO^,_[+/_``0A^"\'AZRBTZSUXV:-_96EQI=^)/$#KTEN6.&"E@</
M,Z1CD+]T+7R=_P`$"XO%'[0O_!4'XQ_'D>$-9T;P3XQM=8EBO)E+VD-S=ZC;
M7*VBS[56:1$5]Q4$#:,XR!7[;2JT%E>*^JX?V=+DLIR?O3E==_+6R/S*I&I+
M'T/:U>>IS7<5M%6?]79^T&>:_&G_`(.%=%L_$?\`P4Z_9?TW4;6WOM/U&2RM
M;JVG0217$4FLQ*Z.IX92I((/!S7[*D<U\9?M_P#_``2<D_;A_:M^%'Q,'CO_
M`(1H?#.6VD_LYM(-V=0\F^6Z_P!9YR>7G8%^ZV.M?)\-X^E@\;[:M+E7+)7\
MW%I'T6>82IB<+[.DKN\7\D]3U5?^"8/[.+9)^`_P?R3G_D4+`_\`M*O3/AM\
M$O"'P5T4Z?X/\+>'/"FG$[FM=(TR"QA9O4K$J@GW-=3;*5#;A@DYIEV/DP!S
MGBO&J8FM.-IR;]6STH480^"*7R/R*_X.+_BYJO[0WQW^#W[+?A&YBEU;Q%J=
MMJFIQH/,V33N]M9"3'(5%-Q,XZ[-C=AG8\(?\$7/VPOA]X3TW1-$_:[N=(T?
M2($M+.QM)-0BM[6)%54CC4/A54#&!7T5\-/^"2$OAC_@J;KO[2^O^._^$CN=
M1:Y?3]$;1O(_LWS(5MXL7!G;=Y<`*`>6N<D\9Y^V2@]!^5?3U>('A,-1P>`<
M7&*O*\8OWWO\2>RT/!I91]8KU<3BTTV[*S:]U;;-;[GX&_\`!43_`()5_M#_
M``,^"H^,'C_XVGXI/X#N+=(FD-T;S2HY;B,":.25B`JS^0<#H3NR,5^P_P#P
M3Z_:CA_;-_8[\`_$=/)6\U_3(QJ4,1REO?1DQ748]A,DF/\`9Q7<?'CX-Z;\
M?/@UXN\$ZM%$^F^+='NM(N"\0D"+/$T>[:<9*E@PY'(&".H\%_X)1_\`!./4
M_P#@FA\(]?\`!UQ\0)?'6FZKJJZI:A]+^P"P=H4CE4+YL@;>41L\8(/7-<V/
MS>./RY4\2TJM.7NV22<7:ZLDEH]2\+ELL)C;T$_9S6MW>S6V^NI\1?\`!N=;
M)<_MU?M3AT5L7:<$9&?[1O:_2+]NO]D#0?VV/V7_`!1\.-8CAMO[;MM]A>!`
M7TV]B(>WN%_W)%&1W4LO1C7CG_!-K_@E&_[`/QX^*?C5O'1\5+\3)4E%I_9'
MV/\`L[%Q-/@OYK^9GS\9POW>G:OLIHU/.!4Y_F<:V:/&82=TN6S\TE^J-,IR
MYT\%]7KQ_FO\VS\FO^#=O]L36_`WB+Q9^RO\2?/L/%?@:[NIM"ANI=[(D4C"
M]L%8G+>5)F5.NY'D(^5!7V#_`,%B?VNF_8V_8(\:^)+&[2U\1ZM"/#^@$GYS
M>W68PZCNT48EFQW\GJ*\P_:L_P"",$OQJ_X*#:!^T%X)^(2_#OQ#I4ME=75M
M%H7VP:C<VS%?,9_/CV^9`!"XVG*\G-=/_P`%8/\`@E7?_P#!3Q/`U@_Q$E\&
M:+X/GN+F6R32#??VC-+Y:JY8SQA=D:.HX/\`K6/'0].)KY;B,SI8R<K0E:51
M6>DMVE;N_P`SGHT\=1P-3#J-Y1O&#[QZ/Y'Y\_\`!-K_`((\?M(ZY^S+H?CS
MX=?'?_A4UA\1+6/5FTRV-VD\T(+BWED:-@&WQ,LB\<+*!7LGQ*_X(B_M;?%_
MP+?^'/%/[6!\2:'J2@76G:BU_/;705E=`R%\<.JL..JBOU>\,^'+/PIH5AI=
MC;0VMAIMO':VT$2!(X(T4*J*HX`````Z`5H%`>PI5N,,PG7E7CRIMW7N0;7;
M5Q;T1I1X<PD*2I23VU]Z5GWTO8_*W_@V6_:1OS\,?'OP&\2*+77OAIJDMY9V
M\CXDCMYIV2ZAV_\`3&[#$D?\_2C`QD_6W_!8Q@__``2Y^-A'0^')2/\`OI*X
M'P5_P2);X8_\%3]6_:0\.>.AI-CKLD[ZGX6BT<E;O[1:K'.#<>>,;YU2XQY7
MWU[GFOH7]L;]G1_VL_V6_&WPW&KOH+>,M-;3C??91<BSRRDOY>Y=WW<8W#KU
M%3CLPPE3-J>.I/W6X2EIL[KF7WIL>#PN)CET\+56J4HKS6O*?)W_``;,?\HS
MH_\`L:M2_P#:5?H._P!PXZXKYV_X)A_L(R?\$Z_V:!\.W\4_\)>%U6YU(7_]
MG_8?]=L^3R_,DZ;>N[G-?1$@W*1V(KS,[Q5/$X^MB*3O&4FUZ-G?E5&='!TZ
M=16:23/QP_8!UZP\/?\`!Q_^T)<ZA>6MC`;76462XD6-&)N;$[<DXS@$X]C7
MZWCXK>&$`'_"2:",=CJ$/_Q5?F/^U]_P;/O^U5^TGXW^(+?&!-%'C/59M3;3
MV\+_`&L6V\CY/,-T@;&.NT=:\V7_`(-&1C_DN<'_`(12_P#R97TF/CE&/E"O
M5Q;A)0C%KD;V5M[H\/!_VAA(RIPH<R<F[\R6_P`F?L1I?CW1?$.H+;:?K&E7
M\^TOY=O=QRN`,<X4DXY'/N*_('_@Y(;?^WI^S%P,-(O7G_F*VE?0'_!,#_@@
MK_P[<_:9D^(O_"RX_%PET6YT@V*^'%L"/-DA?S/,%Q)T\G&-O.[K7H/_``4C
M_P""2DW_``4!^/7PO\<+X\;PJ?AP5)L3HPO?[0Q=0W'#^='Y?^JV]&ZYKBRG
M$8'+<VC5A5YZ:3]ZS6KBU:VO5V.O'4<3C,OE"I3Y9-K2]]%)=?1'TI^TQ^S9
MX4_:S^"^O^`?&FGIJ7A_7X##*G22!P=T<T;?P21N`ZL.0P],@_CO^R%\?/&'
M_!`/]N34O@G\4[JXOO@UXKN_M-CJYCVPPHY\N/5H5R0B_*J74*D["-_)53+^
MX\:8&3DG'.37S=_P4R_X)S>'_P#@I'\!T\)ZE?)X>UW3+Q+_`$37ULENI]+D
MR!*H3<F^.2/*,I8#(1N2BUQY%F=.DI8+&>]0J;_W7TDO-?B=.98"=3EQ6'TJ
MQV\U_*_4^B]#U6WUS2H+RTG@NK2ZC6:">%P\<Z,H*NK#AE((((X(JW7S]_P3
M>_8_\3_L,_LW6WPZU[XAS_$6WTBZ<Z1>W&G?8WT^T94VVFWS9-R(P<J=PPKA
M0`%&?H&O%KPIPJ2C2ES13T?==STZ$YRIJ516;W78CF@$JX/(KP+]H;]@'PI\
M7TNM1TS'AK7)`7:>VA#07#?]-(N!D_WEP?7(XKZ!I&0.,$`@^M>!GG#V79OA
MGA<QI*I'SZ/NFM4_-,];*\WQF75EB,%4<)>77R:V:\F?"VA?&GXL_L3:C!H_
MC+39?$GAIF5()B[2(%SC$5QC(_W)%^F!S7RM^T[_`,%G_CE^VK\8=4^#_P"R
MOX&US39+2Z:RO-;,,<VIA5;9(Y8L;>QBW9`DD=F(&0T;<#]A->\/6'B'3)K*
M_L[:\M+H;)H9HPZ2C'1@>#7/?"'X&>#?@-H<^F^#/#&C>&;&\N7N[B+3[981
M<3.2S2R$#+N23\S$GGK67`645.'*U95ZKQ5&R]E"IJZ33=[RWG&UK)[6TZLO
MBS,(9U3IRITU0JW_`'DH:*:LK>[]EWW:WOT/SB_85_X-OO#WAG6D\<?M"Z[+
M\2_&=X_VNYTGSY)=-CF8DDW$[_OKU\\G=M3)(*N,$_IWX:\*V'A#1[33=,L[
M/3=-T^)8+6TM(%@AMXU&%1$4!54#@``"M%8U0Y"@'V%+BOK\RS7%8^HJF*G>
MVRV2\DMD?/X++Z&%CRT(V[OJ_5A36C+'M3J*\\[!%7:*1TW#\<TZB@!@0A^3
MD4\C-%%`DK#2I/>D,?/&/K3\44!RJ]Q@CQCV-/HHH&-\O/4YI!$`2>YI]%)(
M32>XT*0V<TZBBF"0SRN>OZ4"';P*?10Q<J&QKA1GDT[K110-*PTQ\4!<#']*
M=12L%D-*DD8./PIOEDKU&?I4E&,T6&-VDJ02#1Y?R`<<#%.QBBF`BC:*6C&*
$*`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
